Sandbox Diclofenamide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
Warning
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Overview
Sandbox Diclofenamide is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of elevated intraoculr pressure. There is a Black Box Warning for this drug as shown here. Common adverse reactions include anorexia, nausea, vomiting, drowsiness, paresthesias.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Elevated Intraoculr Pressure
- Dosing Information
- Recommended initial dosage: 100-200 mg PO bid
- Recommended maintenence dosage: 25-50 mg PO qd or bid or tid
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Sandbox Diclofenamide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
- DARANIDE® (dichlorphenamide tablets USP) is contraindicated in hepatic insufficiency.
- Electrolyte Imbalance
- DARANIDE® is contraindicated in renal failure, adrenocortical insufficiency, hyperchloremic acidosis, or in conditions in which serum levels of sodium or potassium are depressed.
- Obstructive Pulmonary Disease
- DARANIDE® should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation since their acidosis may be increased.
- DARANIDE® is contraindicated in patients who are hypersensitive to this product.
Warnings
|
Warning
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Hypokalemia
Potassium excretion is increased by DARANIDE® (dichlorphenamide tablets USP) and hypokalemia may develop. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium supplements such as foods with a high potassium content.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Sandbox Diclofenamide Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Sandbox Diclofenamide Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Sandbox Diclofenamide Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Sandbox Diclofenamide in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sandbox Diclofenamide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Sandbox Diclofenamide during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Sandbox Diclofenamide in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Sandbox Diclofenamide in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Sandbox Diclofenamide in geriatric settings.
Gender
There is no FDA guidance on the use of Sandbox Diclofenamide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Sandbox Diclofenamide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Sandbox Diclofenamide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Sandbox Diclofenamide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Sandbox Diclofenamide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Sandbox Diclofenamide in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Sandbox Diclofenamide Administration in the drug label.
Monitoring
There is limited information regarding Sandbox Diclofenamide Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Sandbox Diclofenamide and IV administrations.
Overdosage
There is limited information regarding Sandbox Diclofenamide overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Sandbox Diclofenamide Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Sandbox Diclofenamide Mechanism of Action in the drug label.
Structure
There is limited information regarding Sandbox Diclofenamide Structure in the drug label.
Pharmacodynamics
There is limited information regarding Sandbox Diclofenamide Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Sandbox Diclofenamide Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Sandbox Diclofenamide Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Sandbox Diclofenamide Clinical Studies in the drug label.
How Supplied
There is limited information regarding Sandbox Diclofenamide How Supplied in the drug label.
Storage
There is limited information regarding Sandbox Diclofenamide Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Sandbox Diclofenamide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Sandbox Diclofenamide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Sandbox Diclofenamide Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Sandbox Diclofenamide interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Sandbox Diclofenamide Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Sandbox Diclofenamide Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.